Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
10 mai 2024 06h00 HE
|
Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT
23 avr. 2024 08h00 HE
|
Tome Biosciences
Tome to present data at ASGCT.
Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
09 avr. 2024 08h08 HE
|
Tome Biosciences
Tome granted US patent for programmable genomic integration.
Tome Biosciences Forms Science and Technology Advisory Committee
04 mars 2024 08h00 HE
|
Tome Biosciences
Tome forms Science and Technology Advisory Committee.
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
30 janv. 2024 08h00 HE
|
Tome Biosciences
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.
Tome Biosciences Acquires Replace Therapeutics
02 janv. 2024 09h00 HE
|
Tome Biosciences
Tome acquires Replace Therapeutics.
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
12 déc. 2023 07h57 HE
|
Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).